- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Supreme Court: Amgen v. Sandoz Briefing Schedule
As reported by Big Molecule Watch, the Supreme Court has ordered a briefing schedule in Amgen v. Sandoz. Because the Court granted and consolidated Sandoz’s petition and Amgen’s conditional cross-petition, the Court has adopted a four-brief schedule, comparable to the procedure used in the courts of appeals.
According to the order, the briefing schedule will be as follows:
- February 10, 2017: Sandoz’s opening brief due. Sandoz will submit its opening brief of up to 15,000 words on the question of whether the BPCIA notice of commercial marketing can be given before FDA approval.
- February 17, 2017: Briefs of amicus curiae in support of Sandoz or in support of neither party due.
- March 10, 2017: Amgen’s response due. Amgen will submit a consolidated brief of up to 19,000 words responding to Sandoz’s opening brief and opening on the question of whether the BPCIA patent dance is mandatory.
- March 17, 2017: Briefs of amicus curiae in support of Amgen due.
- March 31, 2017: Sandoz’s response and reply due. Sandoz will submit a consolidated brief of up to 10,000 words replying to Amgen’s response and responding to Amgen’s opening.
- April 14, 2017: Amgen’s reply due. Amgen will submit a reply to Sandoz’s response of up to 6,000 words.
Amici curiae may file only one brief; the due date is determined by which party the amicus supports, no matter which issue or issues the amicus addresses.
We expect oral argument to occur between April 24-26, the end of the Court’s final argument sitting, which would allow the Court to decide the case before the end of June.
Source: Big Molecule Watch
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Eye on Pharma: EU Aflibercept Approvals; Biosimilars Canada Campaign; Celltrion Data
November 19th 2024The European Commission grants marketing authorization to 2 aflibercept biosimilars; Biosimilars Canada launches new campaign to provide sustainable solutions to employers; Celltrion shares positive data for 2 biosimilars.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Subcutaneous Infliximab CT-P13 Superior to Placebo as Maintenance Therapy for IBD
November 16th 2024In 2 randomized controlled trials of maintenance therapy for inflammatory bowel disease (IBD), the subcutaneous formulation of the infliximab biosimilar CT-P13 demonstrated superiority to placebo in patients with Crohn disease and ulcerative colitis.
